Diagnostic Medical Systems Group (DMS) and FUJIFILM Europe announce, alongside the European Congress of Radiology taking place in Vienna from 1 to 5 March 2017, the conclusion of two commercial and industrial agreements in medical imaging, for the EMEA area and Australia
Fujifilm brings continuous innovation and leading-edge products to a broad spectrum of industries, including healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies.
As a pioneer in diagnostic imaging, Fujifilm is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and as well in the future. From an unrivaled selection of digital flat panel detector and x-ray systems, to the Synapse® brand of PACS, RIS, VNA and cardiovascular products, to advanced women’s health imaging systems. With 271 subsidiaries Fujifilm counts more than 78,000 employees worldwide.
From March 2017, FUJIFILM Europe will integrate the 3D modelling technology, Biomod 3S, developed by AXS Medical, (DMS Group) for diagnostic equipment in spine and posture pathologies, with its new digital flat panel detector D-EVOTM GL.
Designed to capture long length digital images in a single exposure, the FDR D-EVO GL detector (40x120cm) features Fujifilm’s advanced Virtual Grid image and Dynamic Visualization II processing, which can produce exceptional images with contrast and clarity comparable to exams performed with a physical grid while requiring as little as half the dose.
Biomod 3S, in conjunction with the D-EVO GL detector, will provide a unique solution, a simultaneous acquisition of 2D images and 3D modelling images, dedicated to the 2D/3D examination of the spine and eventually, the lower limbs, in (standing) weight-bearing position. It allows a greater accuracy for visualization and follow-up of osteoarticular pathologies by providing the surgeons with additional information essential to the determination of their therapeutic strategies. The solution will be integrated in the Fujifilm range and will be commercialized under the name Visionary 3D GL.
DMS Group and FUJIFILM Europe also concluded a distribution agreement, under the brand name “Visionary”, for the bone densitometry solutions designed and developed by DMS Imaging.
This equipment integrates the highest technologies and performances, especially the proprietary technology "2D-Fan Beam" which offers a maximum image resolution for an examination lasting only 30 seconds. Combining performance, accuracy and ergonomics, these solutions are the ideal partner for doctors requiring an efficient and economical Bone Densitometry solution, allowing “whole body” application, in addition to peripheral imaging. Based on existing Stratos and Stratos dR systems, they will be commercialized by Fujifilm under the names Visionary DEXA and Visionary 3D DEXA.
Hidetoshi Izawa, Marketing Director of FUJIFLM Europe, comments:
Jean-Paul Ansel, CEO of DMS Group, declares:
The Visionary DEXA, Visionary 3D DEXA and Visionary 3D GL solutions will be presented at the Fujifilm booth at the ECR taking place in Vienna, from 1 to 5 March 2017.
About Fujifilm in Europe
Fujifilm entities operate in over 45 group companies in Europe and employ around 4,500 people engaged in R&D, manufacturing, sales, and service. Throughout Europe they serve a range of industries including medical, chemical, graphic systems, electronic materials, optics, recording media, and photographic technologies. FUJIFILM Europe GmbH (Duesseldorf, Germany) acts as Strategic Headquarters for the region and supports its group companies in Europe by formulating marketing and corporate strategies. For more information, please visit www.fujifilm.eu.
About DMS Group
DMS Group is composed of companies with a high innovation potential. First focused on medical imaging industry, it now grows to new horizons. Investing in the future and in research, DMS Group aims to bring tomorrow’s solutions.
DMS Group is present on every continent through a network of over 140 national distributors, branches and joint-ventures. In 2016, DMS Group reached a consolidated turnover of 37.4 M€. DMS Group is listed on Euronext Paris Exchange (ISIN: FR0012202497 - mnémo: DGM). More information on www.dms.com.